NEW YORK (GenomeWeb) – Orig3N, a biotechnology firm developing a disease-modeling platform targeting rare genetically inherited diseases, today announced it raised $3.1 million in a private round of financing. 

The proceeds will go toward expanding Boston-based Orig3N's Life Capsule, a bio-repository for people to contribute their cells via a blood sample. The cells are reprogrammed into induced pluripotent stem cells, which can be used for disease modeling outside the body for medical research, as well as for individualized therapy. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.